Options Trading News

July 30, 2013  Tue 3:47 AM CT

Biotech has been on fire, but traders are bracing for a pullback.

optionMONSTER's Depth Charge monitoring system detected the purchase of 2,500 September 190 puts in the iShares Nasdaq Biotechnology Fund for $4.20. An equal number of September 180 puts were sold at the same time for $1.80. Volume was more than 20 times the previous open interest at each strike, indicating that new positions were initiated.

Owning puts locks in the price where the IBB can be sold, while selling them programs a potential buy order. Combining the two controls a move between the two levels, in this case $190 and $180. It cost $2.40 to implement the strategy, with potential profit of 317 percent on a drop to the lower price. (See the discussion of vertical spreads in our Education section for more.)

The IBB fell 0.86 percent to $194.73 yesterday but is up 42 percent so far this year. The exchange-traded fund has been drifting lower since touching an all-time high of $196.97 last week. The fund's largest holdings include Amgen, Celgene, and Gilead Sciences.

Total option volume was nearly triple the daily average in the session, according to the Depth Charge. Puts outnumbered calls by a bearish 32-to-1 ratio.
Share this article with your friends

Related Stories


How traders are playing the biotechs

January 15, 2016

Our Activity Log shows 11 bullish transactions in the last month, and five bearish ones.


Premium Services

Upcoming Webinar:

Using Options For Income


Jon Najarian and Adam Mesh of Options Wealth Machine discuss a detailed strategy utilizing credit spreads to generate income, and how any level of trader can use this simple trading technique.

Education & Strategy

Sweet Spot Exceptions

As discussed last week, when using the Stock Replacement Strategy to replace a stock position to trade direction, we want to use an option that has very similar characteristics to the stock. We talked about using the deep in-the-money, 80 to 85 delta option that is similar in the Greeks and has relatively little extrinsic value which tends to work against us in stock directional trading.

View more education articles »